91 related articles for article (PubMed ID: 10073143)
1. No mutations of the Smad2 gene in human sporadic gastric carcinomas.
Shitara Y; Yokozaki H; Yasui W; Takenoshita S; Kuwano H; Nagamachi Y; Tahara E
Jpn J Clin Oncol; 1999 Jan; 29(1):3-7. PubMed ID: 10073143
[TBL] [Abstract][Full Text] [Related]
2. Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
Wang D; Kanuma T; Mizunuma H; Takama F; Ibuki Y; Wake N; Mogi A; Shitara Y; Takenoshita S
Cancer Res; 2000 Aug; 60(16):4507-12. PubMed ID: 10969799
[TBL] [Abstract][Full Text] [Related]
3. Mutation analysis of the Smad2 gene in human colon cancers using genomic DNA and intron primers.
Takenoshita S; Tani M; Mogi A; Nagashima M; Nagamachi Y; Bennett WP; Hagiwara K; Harris CC; Yokota J
Carcinogenesis; 1998 May; 19(5):803-7. PubMed ID: 9635866
[TBL] [Abstract][Full Text] [Related]
4. TGF-beta signaling in colon cancer cells.
Li F; Cao Y; Townsend CM; Ko TC
World J Surg; 2005 Mar; 29(3):306-11. PubMed ID: 15711891
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of TGF-beta type II receptor, Smad2, Smad3, Smad4, Smad6 and Smad7 genes in colorectal cancer.
Fukushima T; Mashiko M; Takita K; Otake T; Endo Y; Sekikawa K; Takenoshita S
J Exp Clin Cancer Res; 2003 Jun; 22(2):315-20. PubMed ID: 12866583
[TBL] [Abstract][Full Text] [Related]
6. Mutation of the transforming growth factor-beta type II receptor gene is a rare event in human sporadic gastric carcinomas.
Shitara Y; Yokozaki H; Yasui W; Takenoshita S; Nagamachi Y; Tahara E
Int J Oncol; 1998 May; 12(5):1061-5. PubMed ID: 9538129
[TBL] [Abstract][Full Text] [Related]
7. Mutation analysis of the Smad3 gene in human ovarian cancers.
Wang D; Kanuma T; Takama F; Mizumuma H; Ibuki Y; Wake N; Mogi A; Shitara Y; Hagiwara K; Takenoshita S
Int J Oncol; 1999 Nov; 15(5):949-53. PubMed ID: 10536178
[TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of transforming growth factor beta type II receptor, Smad2, Smad3 and Smad4 in esophageal squamous cell carcinoma.
Osawa H; Shitara Y; Shoji H; Mogi A; Kuwano H; Hagiwara K; Takenoshita S
Int J Oncol; 2000 Oct; 17(4):723-8. PubMed ID: 10995883
[TBL] [Abstract][Full Text] [Related]
9. Abrogation of Smad3 and Smad2 or of Smad4 gene expression positively regulates murine embryonic lung branching morphogenesis in culture.
Zhao J; Lee M; Smith S; Warburton D
Dev Biol; 1998 Feb; 194(2):182-95. PubMed ID: 9501027
[TBL] [Abstract][Full Text] [Related]
10. A novel dominant negative Smad2 mutation in a TGFbeta resistant human carcinoma cell line.
Tsang KJ; Tsang D; Brown TN; Crowe DL
Anticancer Res; 2002; 22(1A):13-9. PubMed ID: 12017275
[TBL] [Abstract][Full Text] [Related]
11. TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines.
Fink SP; Mikkola D; Willson JK; Markowitz S
Oncogene; 2003 Mar; 22(9):1317-23. PubMed ID: 12618756
[TBL] [Abstract][Full Text] [Related]
12. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells.
Poncelet AC; de Caestecker MP; Schnaper HW
Kidney Int; 1999 Oct; 56(4):1354-65. PubMed ID: 10504488
[TBL] [Abstract][Full Text] [Related]
13. Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF-beta.
Feng XH; Lin X; Derynck R
EMBO J; 2000 Oct; 19(19):5178-93. PubMed ID: 11013220
[TBL] [Abstract][Full Text] [Related]
14. Genomic structure of the human Smad3 gene and its infrequent alterations in colorectal cancers.
Arai T; Akiyama Y; Okabe S; Ando M; Endo M; Yuasa Y
Cancer Lett; 1998 Jan; 122(1-2):157-63. PubMed ID: 9464505
[TBL] [Abstract][Full Text] [Related]
15. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.
Tian F; Byfield SD; Parks WT; Stuelten CH; Nemani D; Zhang YE; Roberts AB
Cancer Res; 2004 Jul; 64(13):4523-30. PubMed ID: 15231662
[TBL] [Abstract][Full Text] [Related]
16. Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Qiu W; Schönleben F; Li X; Su GH
Cancer Lett; 2007 Jan; 245(1-2):163-70. PubMed ID: 16478646
[TBL] [Abstract][Full Text] [Related]
17. Alterations of the transforming growth factor-beta signaling pathway in hepatocellular carcinomas induced endogenously and exogenously in rats.
Sasaki Y; Tsujiuchi T; Murata N; Tsutsumi M; Konishi Y
Jpn J Cancer Res; 2001 Jan; 92(1):16-22. PubMed ID: 11173539
[TBL] [Abstract][Full Text] [Related]
18. Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells.
Sugano Y; Matsuzaki K; Tahashi Y; Furukawa F; Mori S; Yamagata H; Yoshida K; Matsushita M; Nishizawa M; Fujisawa J; Inoue K
Oncogene; 2003 Apr; 22(15):2309-21. PubMed ID: 12700666
[TBL] [Abstract][Full Text] [Related]
19. Expression and mutational analysis of the MADR2/Smad2 gene in human prostate cancer.
Latil A; Pesche S; Valéri A; Fournier G; Cussenot O; Lidereau R
Prostate; 1999 Sep; 40(4):225-31. PubMed ID: 10420150
[TBL] [Abstract][Full Text] [Related]
20. Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2.
Muro-Cacho CA; Rosario-Ortiz K; Livingston S; Muñoz-Antonia T
Clin Cancer Res; 2001 Jun; 7(6):1618-26. PubMed ID: 11410498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
